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Triple-Transgenic Model of Alzheimer’s
Disease with Plaques and Tangles:
Intracellular A and Synaptic Dysfunction
Scheff et al., 1991). Notably, the memory and cognitive
decline observed in AD patients correlates better with
the synaptic pathology than either plaques or tangles,
and thus, synaptic dysfunction is likely the most signifi-
cant factor contributing to the initial stages of memory
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ral dementia with parkinsonism linked to chromosome
17 kindreds facilitated the development of tauopathies
in transgenic mice (Gotz et al., 2001a; Higuchi et al.,Summary
2002; Lewis et al., 2000). One surprising aspect of the
overwhelming majority of extant AD models has beenThe neuropathological correlates of Alzheimer’s dis-
ease (AD) include amyloid- (A) plaques and neuro- that the successful development of one hallmark patho-
logical lesion has in and of itself been insufficient tofibrillary tangles. To study the interaction between A
and tau and their effect on synaptic function, we de- trigger the development of the other signature lesion.
Consequently, the concomitant manifestation of bothrived a triple-transgenic model (3Tg-AD) harboring
PS1M146V, APPSwe, and tauP301L transgenes. Rather than plaques and tangles has required the introduction of
multiple transgenes into the same mouse, which hascrossing independent lines, we microinjected two
transgenes into single-cell embryos from homozygous generally been achieved by crossing several indepen-
dent transgenic lines, or alternatively, by microinjectingPS1M146V knockin mice, generating mice with the same
genetic background. 3Tg-AD mice progressively de- pathological protein into the brains of single-transgenic
mice (Gotz et al., 2001b; Lewis et al., 2001).velop plaques and tangles. Synaptic dysfunction, in-
cluding LTP deficits, manifests in an age-related man- Here, we describe the development of a novel triple-
transgenic model (3Tg-AD). Instead of crossing threener, but before plaque and tangle pathology. Deficits
in long-term synaptic plasticity correlate with the ac- independent lines, we derived our transgenic model by
directly introducing two additional transgenes into thecumulation of intraneuronal A. These studies suggest
a novel pathogenic role for intraneuronal A with re- germline of a genetically modified mouse. We report
that (to our knowledge) this is the first transgenic modelgards to synaptic plasticity. The recapitulation of sa-
lient features of AD in these mice clarifies the relation- to develop both plaque and tangle pathology in AD-
relevant brain regions. The 3Tg-AD mice develop ex-ships between A, synaptic dysfunction, and tangles
and provides a valuable model for evaluating potential tracellular A deposits prior to tangle formation, consis-
tent with the amyloid cascade hypothesis. These miceAD therapeutics as the impact on both lesions can be
assessed. exhibit deficits in synaptic plasticity, including long-term
potentiation (LTP) that occurs prior to extracellular A
Introduction deposition and tangles but is associated with intracellu-
lar A immunoreactivity. Double-transgenic mice (2Tg)
Alzheimer’s disease (AD), a progressive neurodegenera- lacking the human APP transgene (but containing
tive disorder that is the most common cause of dementia PS1M146V and tauP301L) do not develop any extracellular
in the elderly, is characterized by two hallmark lesions: plaques nor do they show any significant intraneuronal
diffuse and neuritic plaques, which are predominantly A immunoreactivity. Notably, the 2Tg mice do not
composed of the A peptide, and neurofibrillary tangles, exhibit any LTP deficits, despite expressing the tau
composed of filamentous aggregates of hyperphos- transgene to comparable levels as the 3Tg-AD mice.
phorylated tau protein (Selkoe, 2001). Loss of neuronal Therefore, such findings suggest a novel pathophysio-
synaptic density and synapse number represent another logic role for intraneuronal A and indicate that synaptic
invariant feature of the disease that appears to precede dysfunction is a proximal defect in the pathobiology of
overt neuronal degeneration (DeKosky and Scheff, 1990; AD, preceding extracellular plaque formation and tan-
gles. These 3Tg-AD mice will be useful for studying
the impact of A and tau on synaptic plasticity and for* Correspondence: laferla@uci.edu
5 These authors contributed equally to this work. evaluating the efficacy of anti-AD therapies in mitigating
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Figure 1. Generation of 3Tg-AD Mouse Model
(A) Strategy used to develop 3Tg-AD mice. Using the pronuclear microinjection technique, we coinjected two independent transgene
constructs encoding human APPSwe and tauP301L (4R/0N), both under the control of the mouse Thy1.2 regulatory elements, into single-cell
embryos harvested from mutant homozygous PS1M146V knockin mice. The entire mouse Thy1.2 genomic sequence is shown with exons depicted
as boxes and noncoding sequences as thin lines. The injected embryos were reimplanted into foster mothers and the resulting offspring
genotyped to identify 3Tg-AD mice.
(B) Genotypic analysis for identification of homozygous mice. Representative Southern blot comparing the gene dosage of the human tau
and APP transgenes from tail DNA of hemizygous and homozygous mice. Analysis of the transgene transmission frequency confirmed that
the mice were homozygous.
(C) Tau and APP expression are doubled in the homozygous mice. Immunoblot comparing steady-state levels of human APP and tau proteins
in the brains of 4-month-old hemizygous and homozygous 3Tg-AD mice from the B1 and G6 lines. For APP (detected with antibody 22C11)
and tau (detected with antibody tau5), the levels are doubled in the homozygous mice. Antibodies 22C11 and tau5 recognize both human
and mouse APP and tau, respectively.
(D) Steady-state levels of the APP and tau protein are approximately 3- to 4-fold and 6- to 8-fold higher than endogenous levels in hemizygous
and homozygous mice from the B1 line and 2-fold and 4-fold higher in hemizygous and homozygous mice from the G6 3Tg-AD line.
the neurodegenerative effects mediated by both signa- locus, we reasoned there was a high probability that the
ture lesions. tau and APP transgene cassettes would likely cointe-
grate into the same site. Six founder lines were identi-
fied, five of which were found to harbor all three trans-Results
genes. Founder mice were backcrossed to PS1-KI mice.
Genotype analysis by Southern blotting indicated thatDerivation and Characterization of 3Tg-AD Mice
the tau and APP transgenes integrated at the same locusRather than crossing three transgenic lines, we comicro-
in the majority of the founder lines (data not shown). Ininjected two independent transgenes encoding human
at least two lines (B1 and G6), the transgenes appearedAPPSwe and human tauP301L (both under control of the
to cointegrate at the same locus based on analysis ofmouse Thy1.2 regulatory element) into single-cell em-
the transmission frequency, which showed that eachbryos harvested from homozygous mutant PS1M146V
transgene did not independently assort in subsequentknockin (PS1-KI) mice (Figure 1A). Because rarely does
a single copy of any transgene integrate into a particular generations (Table 1). Therefore, comicroinjection of dif-
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Table 1. Cotransmission Frequency of the APP and Tau Transgenes in the 3Tg-AD Lines
Number of Number of Total Number Transgene
Hemizygous Offspring Transgene Percent Coinherited Cotransmission
Mouse Line Litters Generated (NonTg  Tg) Positive Mice Transgenic APP and tau Frequency
3Tg-AD B1 30 236 146 61.8% 146 100%
3Tg-AD G6 8 64 29 45.3% 29 100%
2Tg A1 13 104 45 43.3% NA NA
Analysis of the inheritance pattern of the human tau and APP transgenes in two 3Tg-AD lines, B1 and G6, revealed that both were
inherited with 100% frequency. These data suggest that both transgenes cointegrated at the same locus and, thus, would be transmitted as
nonsegregating units. Data from the A1 2Tg line (PS1M146V/TauP301L) are also shown. All lines were backcrossed to the PS1-KI strain to maintain
the M146V mutation.
ferent transgenes appears to be a viable and effective clusively, restricted to the CNS (Figure 2A). To determine
which regions of the CNS expressed the human APP andmeans of generating multitransgenic mice.
tau proteins, we microdissected and prepared proteinBecause the APP and tau transgenes cointegrated at
extracts from multiple brain regions (hippocampus, cor-the same site and thus are unlikely to independently
tex, cerebellum, etc.) and measured steady-state levelsassort, and because the M146V mutation was “knocked
of the transgenic proteins by immunoblotting usingin” to the endogenous mouse PS1 locus (Guo et al.,
human-specific antibodies (Figure 2B). We found that1999), these 3Tg-AD mice essentially breed as readily
AD-relevant regions, including the hippocampus andas a “single” transgenic line, even though the mice con-
cerebral cortex, were among the regions containing thetain three transgenes. This facilitates the establishment
highest steady-state levels of both the transgene-and maintenance of the mouse colony. Moreover, this
derived human APP and tau proteins. Other regions, suchstrategy results in another important pragmatic benefit,
as the cerebellum, did not appear to contain any trans-as the 3Tg-AD mice are of the same genetic back-
genic proteins, either because they are not expressedground, thereby reducing a confounding biological vari-
there or are rapidly degraded.able that is unavoidable when crossing independent
To determine whether APP was processed to liberatetransgenic lines.
the A peptide, we analyzed brain homogenates fromWe next crossed hemizygous F1 mice to each other hemizygous and homozygous mice by immunoprecipi-
to determine if mice homozygous for all three transgenes
tation/Western blotting. Figure 2C shows the presence
(PS1M146V, tauP301L, APPSwe) could be derived. A doubling of a 4 kDa species after probing with an A-derived
of gene dosage is apparent in selected mice by Southern antibody that is twice as abundant in the homozygous
blotting (Figure 1B). These putative homozygous mice versus hemizygous brains but is undetectable in NonTg
were backcrossed to nontransgenic (NonTg) mice and brain homogenates. We also compared A40 and A42
resulted in the expected 100% transmission of the trans- levels in the brains of age- and gender-matched NonTg
genes to the subsequent generation, confirming that and hemizygous and homozygous 3Tg-AD mice by
the mice were indeed homozygous (data not shown). sandwich ELISA. There is a progressive increase in A
Homozygous mice were established for both the B1 and formation as a function of age in the 3Tg-AD brains
G6 lines. Besides further facilitating breeding efforts and and a particularly pronounced effect on A42 levels (Fig-
ure 2D). As anticipated, A levels are higher in the homo-the need to genotype the progeny, steady-state levels
zygous mice relative to the hemizygous mice.of human tau and APP transgene products are doubled
in the homozygous mice (Figure 1C). Using antibodies
A Precedes Tangle Formation in 3Tg-AD Micethat recognize both human and mouse APP or tau, we
Intraneuronal A immunoreactivity is one of the earliestfound that in the B1 line steady-state levels of each
neuropathological manifestations in the both the B1 andtransgenic product were3- to 4-fold and6- to 8-fold
G6 3Tg-AD mice, first detectable in neocortical regionshigher than endogenous levels in the brains of the hemi-
and subsequently in CA1 pyramidal neurons. Intracellu-zygous and homozygous mice, respectively (Figure 1D).
lar A immunoreactivity is apparent between 3 andLikewise, APP and tau levels were 2-fold and 4-fold
4 months of age in the neocortex of 3Tg-AD micehigher in hemizygous and homozygous G6 3Tg-AD
(Figure 3A) and by 6 months of age in the CA1 subfieldmice (Figure 1D). The maintenance of both hemizygous
of the hippocampus of hemizygous and homozygous
and homozygous 3Tg-AD mice renders it possible to
mice (Figure 3D). As with the intraneuronal A immuno-
study the effect these gene interactions exert as a func- reactivity, extracellular A deposits first became appar-
tion of age, in a context in which the expression levels ent in 6-month-old mice in the frontal cortex, predomi-
are doubled in mice of the same genetic background. nantly in layers 4 to 5, and were readily evident by 12
The mouse Thy1.2 expression cassette has been months (Figures 3B and 3C). Also by this time point,
demonstrated to drive transgene expression predomi- extracellular A deposits were evident in other cortical
nantly to the CNS (Caroni, 1997). Protein extracts from regions and in the hippocampus (Figures 3E and 3F),
multiple tissues from the B1 3Tg-AD line (the highest suggesting that there is an age-related, regional depen-
expressing line) were analyzed by Western blot using dence to A deposition in the 3Tg-AD mice. The ELISA
human-specific antibodies targeted to APP or tau and data further corroborate the progressive increase in A
deposition (Figure 2D).confirmed that expression was predominantly, if not ex-
Neuron
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Figure 2. Analysis of Steady-State Levels of the Human Transgene Products in 3Tg-AD Mice
(A) Multiple peripheral tissues were surveyed by immunoblot analysis to determine the transgene expression profile. Tau and APP appear to
be exclusively expressed in the CNS. Antibodies HT7 and 6E10 were used to detect human-specific tau and APP, respectively.
(B) Quantitative comparison of transgene products in various brain subregions by Western blotting with either antibodies HT7 (tau) or 6E10
(A). The hippocampus and cerebral cortex, two prominent AD-afflicted regions, are among the brain regions containing the highest steady-
state levels of the human transgene products.
(C) A levels are doubled in the homozygous mice. Immunoprecipitation/Western blotting shows that 4 kDa A is detectable in the brains of
both hemizygous and homozygous mice.
(D) A40 and A42 levels were measured by ELISA from different-aged mice (n  3/group), as described previously (Suzuki et al., 1994).
NonTg, hemizygous, and homozygous mice are depicted as gray, white, and black bars, respectively. Statistical difference between hemizygous
and NonTg mice is denoted by “**,” whereas “*” indicates that homozygous mice are statistically different from hemizygous and NonTg mice.
Although it is difficult to ascertain with complete cer- of the G6 line as well (Figure 7G). In addition, we show
that many of these extracellular A deposits in oldertainty, based on the use of end-specific A antibodies,
some (if not most) of the intracellular immunoreactive mice are also thioflavin S positive (cf. Figures 4E and
4F) and that reactive astrocytes colocalize with somematerial is A42 (Figure 4; also see below). The A42-
specific antibody recognizes many extracellular depos- extracellular A deposits (Figure 4G).
Because of the approach used to generate the 3Tg-its in the neocortex and hippocampus of mice from the
B1 3Tg-AD line (Figures 4A–4E). This antibody also AD mice, both the tau and APP transgenes are ex-
pressed to comparable levels in the same brain regions.immunolabels neurons in the hippocampus and cortex
Triple-Transgenic Model of Alzheimer’s Disease
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Figure 3. A Deposition Precedes Tau Pathology in 3Tg-AD Mice
(A) A immunoreactivity is first detected intracellularly in neurons within the neocortex.
(B and C) Low- and high-magnification views, respectively, of the neocortex from a 9-month-old homozygous mouse showing extracellular
A deposits in layers 4 to 5 of the neocortex.
(D and E) Hippocampi of homozygous 3Tg-AD mice (6- and 12-months-old, respectively) showing first intraneuronal A staining in the
pyramidal neurons in the CA1 region (D) and then with extracellular A deposits (E).
(F) High-magnification view of section shown in (E).
(G and H) Human tau immunoreactivity, detected with the human-specific anti-tau antibody HT7 is first apparent in the hippocampus and
becomes more intense with advancing age (6- to 12-months-old, respectively).
(I) High magnification of section shown in (H). (A)–(F) show A immunoreactivity using monoclonal antibody 1560; (G)–(I) show tau immunostaining
with antibody HT7.
Original magnifications: 5 (B, D, E, G, and H), 10 (A), 20 (F and I), and 40 (C).
Consequently, this enabled us to directly test the amy- human tau protein. Conformational-specific antibody
MC1 (Figures 5A and 5B) and phospho-tau antibodiesloid cascade hypothesis, which predicts that A is the
initiating trigger that underlies all cases of AD (Hardy AT180, which detects phosphorylated threonine 231
(Figures 5D and 5E); AT8, which detects tau phosphory-and Selkoe, 2002). We compared the development of
A and tau pathology in 3Tg-AD mice. Although extra- lated at serine 202 and threonine 205 (Figures 5G and
5H); and PHF1, which detects serine 396 and 404 phos-cellular A deposits in cortex are apparent by 6 months
of age (and even earlier for intracellular A immunoreac- phorylated sites, were used to identify affected neurons
(Figures 5K and 5L). Between 12 to 15 months of age,tivity), no tau alterations are apparent at this age (Figure
3G). It is not until the 3Tg-AD mice reach about 12 MC1-, AT180-, and AT8-reactive neurons were readily
apparent, although staining with PHF1 did not becomemonths of age that extensive human tau immunoreactivity
is first evident in CA1 neurons, with prominent immuno- evident until the mice were about 18 months of age.
None of these antibodies bind to normal tau, nor werelabeling of the somatodendritic compartments (Figures
3H and 3I). Therefore, despite the comparable over- any of these immunoreactive structures detected in
NonTg brains (Figure 5C). Thus, tau is conformationallyexpression of these two mutant proteins, A pathology
develops much earlier than the tau pathology, consis- altered and hyperphosphorylated at multiple residues
in the brains of the 3Tg-AD mice in an age-related andtent with the amyloid cascade hypothesis.
regional-dependent manner. In addition, histological
stains, such as Gallayas and thioflavin S, also identifyNeurofibrillary Alterations
Tau pathology is first apparent in the hippocampus of altered tau-reactive neurons, indicating that some of the
accumulating tau proteins form aggregates (Figures 5Ithe 3Tg-AD, particularly within pyramidal neurons of
the CA1 subfield, and then later progresses to involve and 5J).
Tau-reactive dystrophic neurites were also evidentcortical structures (Figure 5F). This closely mimics the
distribution pattern that occurs in human AD brains surrounding globular structures in older 3Tg-AD brains
(18 months, Figure 5M). These globular structures were(Mesulam, 2000). We also confirmed the presence of
tau-reactive neurons in the hippocampus and amygdala thioflavin positive as revealed by analysis of serial sec-
tions (cf. Figure 5M with Figure 4F). The 3Tg-AD miceof 3Tg-AD mice from the G6 line (Figures 7H and 7I).
Conformational- and phospho-specific tau antibodies develop a progressive and age-dependent A and tau
pathology, although A deposits manifest prior to tanglerevealed an age-related progression in alterations of the
Neuron
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Figure 4. A Deposition Initiates in the Neocortex and Progresses to the Hippocampus
(A) Low-magnification view of neocortex from an aged 3Tg-AD mouse following staining with A42-specific antibody.
(B and C) Higher-magnification views of section in (A) showing extracellular plaque and intraneuronal A immunoreactivity following staining
with A42-specific antibody.
(D) Low-magnification view of hippocampus from 18-month-old 3Tg-AD mouse with the A42-specific antibody showing the number of
A42-reactive plaques.
(E and F) High-magnification view of subicular/CA1 region of panel shown in (D), and (F) a serial section following thioflavin S staining.
(G) Double labeling immunohistochemistry in which astrocytes are reacted with anti-GFAP antibodies and stained brown with DAB, and A
is reacted with antibody 6E10 and developed with true blue.
(H and I) A and tau colocalize to many of the same pyramidal neurons. Low- (H) and high- (I) magnification views in which Awas immunostained
with 6E10 followed by detection with true blue, whereas tau was immunostained with antibody HT7 and detected using DAB (brown staining).
Mouse ages are 12 months, (G)—(I), and 18 months, (A)—(F).
Original magnifications: 5 (A and D), 10 (E, F, and H), 20 (B, C, and G), 40 (I).
formation. However, as has been reported, it is likely that dysfunction, for example, is among the best correlates
for the memory and cognitive changes that characterizeA pathology affects the development of tau pathology
(Gotz et al., 2001b; Lewis et al., 2001). Although A and AD (DeKosky and Scheff, 1990; Scheff et al., 1991). We
compared 1- and 6-month-old homozygous 3Tg-ADtau pathology initiate in different brain regions in the
3Tg-AD mice (i.e., cortex for A and hippocampus mice to determine if there was an age-related impair-
ment in synaptic function in the CA1 hippocampal re-for tau), it is not inconsistent with the notion that A
influences tau pathology. The finding that tau and A gion. Age- and gender-matched NonTg and PS1-KI mice
immunoreactivity colocalize to the same neurons, as were used as controls. PS1-KI mice were evaluated be-
revealed by double-labeling immunohistochemistry, fur- cause their electrophysiological properties were un-
ther supports the concept that A is poised to influence known and because the 3Tg-AD mice were directly
tau (Figures 4H and 4I). Consequently, it is likely that derived from this line. Thus, it was crucial to determine
soluble intracellular A (or an intracellular A-containing the effect of the PS1 mutation on synaptic function. In
APP derivative), which is the first detected pathological addition, the 6 month time point was selected because
manifestation, affects the development of the tau pa- extracellular A deposits are evident only in the neocor-
thology. A42-specific epitopes are also found to be tex and not in the CA1 region of the hippocampus, al-
associated with intracellular neurofibrillary tangles in the though intracellular A immunoreactivity is apparent.
AD brain (Grundke-Iqbal et al., 1989; Schwab and This allowed us to determine the pathobiological signifi-
McGeer, 2000). cance of the intracellular A species.
To investigate basal synaptic transmission, we gener-
ated input/output (I/O) curves by measuring field-excit-Synaptic Dysfunction Is an Early
Phenotypic Manifestation atory postsynaptic potentials (fEPSPs) elicited in CA1
by stimulation of the Schaffer collaterals at increasingNeuronal and synaptic dysfunction are major pheno-
typic manifestations of AD neuropathology. Synaptic stimulus intensities. The I/O curves between 1-month-
Triple-Transgenic Model of Alzheimer’s Disease
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Figure 5. Neurofibrillary Tangles Initiate in the Hippocampus and Progress to the Neocortex
(A and B) Low- and high-magnification views of the hippocampus showing human tau immunopositive pyramidal neurons following staining
with the conformational specific antibody MC1.
(C) No altered tau epitopes are present in the hippocampus of NonTg mouse following staining with antibodies HT7, MC1, AT8, AT180, or
PHF. Representative section stained with AT8.
(D and E) Low- and high-magnification views of the hippocampus showing tau immunoreactive pyramidal neurons following staining with
antibody AT180, which detects phosphorylated tau proteins at threonine 231 residues.
(F) Immunostaining of neocortex with the human-specific tau antibody HT7.
(G and H) Low- and high-magnification view showing immunopositive neurons following staining with antibody AT8, which detects phosphory-
lated tau proteins at serine 202 and threonine 205 residues.
(I and J) High-magnification view from 12-month-old homozygous mice stained with Gallyas silver stain and thioflavin S, respectively, indicating
that the accumulating tau proteins form aggregates.
(K and L) Low- and high-magnification view showing immunopositive neurons following staining with antibody PHF1, which detects serine
396- and 404-phosphorylated residues.
(M) High-magnification view of the subiculum showing tau-reactive dystrophic neurites surrounding globular structures, which are thioflavin-
positive A plaques (see Figure 4F).
Original magnifications: 5 (A, C, D, G, and K), 10 (F), 20 (B, E, H, and L), 40 (M), 100 (I and J).
old PS1-KI and 3Tg-AD mice were not significantly (Thomson, 2000). The enhancement of facilitation in the
PS1-KI mice may be due to alterations in handling intra-different from NonTg mice (Figure 6A). In contrast,
6-month-old PS1-KI and 3Tg-AD mice exhibited cellular Ca2 (LaFerla, 2002; Leissring et al., 2000), which
can be negated by overexpression of APP in the 3Tg-smaller fEPSP slopes and amplitudes at all stimulus
intensities tested and had significantly reduced maxi- AD mice (see below for comment on tau).
Long-term potentiation (LTP), a form of plasticitymum fEPSPs relative to NonTg mice (Figure 6B). The
PS1-KI mice, however, were not significantly different thought to underlie learning and memory (Bliss and Col-
lingridge, 1993), was investigated in the CA1 hippocam-from the 3Tg-AD mice. These results show that basal
synaptic transmission is impaired in both the PS1-KI pal region. No differences were observed among any
of the mouse lines at 1 month of age (Figure 6E). Weand 3Tg-AD mice by 6 months of age.
We investigated paired-pulse facilitation (PPF), a mea- investigated LTP in 6-month-old 3Tg-AD mice. Our
initial experiments showed that LTP was severely im-sure of short-term plasticity. No differences in PPF were
observed among 1-month-old NonTg, PS1-KI, and paired in the 3Tg-AD mice. However, because the LTP
induction protocol used a stimulus intensity that elicited3Tg-AD mice (Figure 6C). At 6 months of age, there
was no difference in the amount of facilitation between 30% of the maximum fEPSP slope during baseline, it
is plausible that the smaller absolute fEPSP may accountNonTg and 3Tg-AD mice; however, the PS1-KI mice
exhibited significantly enhanced PPF compared to for the LTP deficits. To address this possibility, in some
experiments, we increased the stimulus intensity of theNonTg mice (Figure 6D). The mechanisms underlying
PPF are thought to be presynaptic (Zucker and Regehr, 3Tg-AD mice to match baseline fEPSP magnitudes to
those of NonTg mice. The stimulus intensity used to2002) and probably involve residual Ca2 in the nerve
terminal after the first stimulus, leading to increased elicit LTP in the NonTg sections was approximately 30%
of the maximum fEPSP slopes, equating to a value ofneurotransmitter release during the second stimulus
Neuron
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Figure 6. Age-Related Synaptic Dysfunction in 3Tg-AD Mice
(A) Input/output (I/O) curves and representative fEPSPs at increasing stimulus strengths are shown for NonTg, PS1-KI, and 3Tg-AD mice,
showing no differences at 1 month of age.
(B) Smaller fEPSPs are evoked in six-month-old PS1-KI, tau-PS1 double-transgenic, and 3Tg-AD mice compared to NonTg mice, indicating
impaired synaptic transmission. NonTg, 1.42mV/ms  0.17mV/ms, n  12 slices from six mice; PS1-KI, 0.60mV/ms  0.06mV/ms, in n  14/8,
p  0.001; tau-PS1, 0.69  0.05, n  7/3; 3Tg-AD, 0.53mV/ms  0.06mV/ms, n  14/6, p  0.001.
(C) Paired-pulse facilitation (PPF) was measured at an interpulse interval of 50 ms and was normal for all groups at 1 month of age.
(D) At 6 months of age, 3Tg-AD mice exhibited normal PPF compared to NonTg mice (NonTg, 31%  1.5%; 3Tg-AD 30%  2.7%, p 
0.5), but PS1-KI mice exhibited significantly enhanced PPF (44%  2.9%, p  0.01). The double-transgenic mice also showed enhanced PPF
(43%  2.9%), indicating that mutant tau overexpression did not impact the PS1-mediated effect on PPF.
(E) fEPSP slopes were recorded and were expressed as the percentage of the pretetanus baseline. Representative fEPSPs before (solid line)
and 60 min after the induction of LTP (dotted line) are shown. LTP was normal in all groups at 1 month of age.
(F) LTP was markedly impaired in 3Tg-AD mice. In contrast, short-term LTP was enhanced in PS1-KI mice but was otherwise normal. The
amount of potentiation of fEPSPs between 0 and 10 min after HFS was 232%  13% in NonTg mice (n  12/6) and was significantly higher
in PS1-KI mice (282%  19%, n  14/8, p  0.05) but was significantly reduced in 3Tg-AD mice (143%  6%, n  14/6, p  0.001). LTP
in the 2Tg double-transgenic mice was normal and similar to that observed in the NonTg mice, but both groups were significantly lower
than PS1-KI mice (219%  6%, n  7/3). The amount of potentiation between 50 to 60 min after HFS was 190%  11% in NonTg mice and
was not significantly different in PS1-KI mice (212%  13%, p  0.1) or 2Tg mice (182%  12%, p  0.1) but was significantly reduced in
3Tg-AD mice (125%  8%, p  0.001).
0.45mV/ms, which is below the max value of the 3Tg- matched to NonTg levels, with the experiments where
the normal LTP protocol was used. We also pooled theAD and PS1-KI mice. LTP magnitudes in these experi-
ments did not significantly differ in the percentage of data from the NonTg experiments, where baseline
fEPSPs were lowered to 3Tg-AD levels, with data frompotentiation when these stronger stimulus intensities
were used (nonraised 115%  11%, n  8/4; raised the normal LTP protocol. The pooled data show reduced
LTP in the 3Tg-AD as compared to NonTg mice (Figure139% 10%, n 6/2, p 0.06), indicating that reduced
basal transmission does not likely account for the defi- 6F). In contrast, in the PS1-KI mice, LTP was essentially
normal despite also having weaker fEPSPs relative tocits in LTP in the 3Tg-AD mice. In some experiments,
we also lowered the baseline fEPSP of the NonTg mice NonTg controls (Figure 6B). There was, however, a trend
in the PS1-KI mice for significantly higher potentiationto match 3Tg-AD mice and found no difference in
potentiation as compared with the normal LTP protocol during the first 10 min after HFS, as also reported in
transgenic mice overexpressing the PS1A246E variant(data not shown). We therefore pooled all the data from
the 3Tg-AD experiments, where baseline fEPSPs were (Parent et al., 1999). As with the 3Tg-AD mice, raising
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baseline fEPSPs to NonTg levels did not result in signifi- lized a novel antibody, A11, that selectively recognizes
protofibrillar A species (Kayed et al., 2003). Althoughcantly different LTP, and thus, the data were pooled.
we could readily detect protofibrillar A species in the
hippocampus of older 3Tg-AD mice, we failed to de-Intracellular A Underlies
tect any extracellular protofibrillar A staining in the 6the Synaptic Dysfunction
month-old mice used for the electrophysiological stud-One-month-old 3Tg-AD mice did not exhibit deficits
ies (cf. Figures 7J–7L). Therefore, if there is any extracel-in synaptic plasticity, and likewise, hippocampal brain
lular protofibrillar A in the hippocampus at this timesections did not show any intracellular A immunoreac-
point, it occurs below the limit of detection, renderingtivity. At 6 months of age, synaptic dysfunction and LTP
it unlikely to exert such profound physiological effects,deficits were already apparent in the 3Tg-AD mice.
and we conclude that the synaptic dysfunction is likelyAlthough no extracellular A deposits are localized to
due to the intraneuronal accumulation of A.the hippocampal region at this age (Figure 3D), many
pyramidal cells in the CA1 subfield were found to be
strongly immunoreactive following immunostaining with Discussion
a variety of antibodies that recognize A epitopes, in-
cluding antibodies 4G8, 6E10, 1560, and end-specific We used a novel strategy to develop a triple-transgenic
model of AD. Compared to crossbreeding, this approachantibodies that selectively recognize A42 (Figure 7B).
These data suggest that the intraneuronal accumulation produces several major advantages. The APP and tau
transgenes cointegrated at the same genetic locus, ren-of A underlies the observed synaptic dysfunction. To
test this hypothesis, we derived double-transgenic mice dering it unlikely that either transgene will independently
assort in subsequent generations. Consequently, this(2Tg) that harbored the human PS1M146V KI mutation
and the tauP301L transgene but that lacked the human tight linkage coupled to the knockin of the PS1 mutation
indicates that the 3Tg-AD mice breed as readily asSwedish APP transgene. As expected, because the
2Tg mice do not overexpress APP, we could find no any single-transgenic line, particularly because these
mice have also been bred to homozygosity. Thus, deriv-evidence of intraneuronal A accumulation (Figure 7C).
As with the 3Tg-AD mice, both hemizygous and homo- ing a large colony is straightforward, cost effective, and
does not require extensive genotyping of the progeny.zygous 2Tg mice were established. We found that the
hemizygous 2Tg mice expressed human tau 6-fold Moreover, the easy propagation of this transgenic line
facilitates their crossing to other transgenic or gene-over endogenous mouse tau, comparable to steady-
state levels of human tau in the B1 3Tg-AD homozy- targeted mice to assess the impact of other genotypes
on the neuropathological or physiological phenotype. Itgous mice (Figure 7D). Therefore, because the expres-
sion of PS1 and tau was equivalent between the 2Tg is important to note, however, that even the hemizygous
mice develop the same neuropathological changes, al-and 3Tg-AD mice, we could directly assess the conse-
quences of APP overexpression on synaptic activity be- beit with a slightly delayed onset. Therefore, crossing
these mice to other genetically modified mice does nottween these two transgenic lines.
As shown in Figure 6B, basal synaptic transmission require returning the original three transgenes to a ho-
mozygous state. Finally, another major advantage withis impaired in the 2Tg mice to a similar degree as in
the PS1-KI and the 3Tg-AD mice. Notably, PPF in the this approach is that multiple transgenes are introduced
into an animal without altering or mixing the background2Tg mice was similar to the PS1-KI mice (Figure 6D),
suggesting that expression of mutant tau had no effect genetic constitution. Thus, an important confounding
variable is avoided, which may be a crucial parameteron the facilitation mediated by mutant PS1. In contrast,
overexpression of APP negates the PS1-mediated effect for behavioral, electrophysiological, and vaccine-based
experiments.on PPF (Figure 6D). To determine if LTP was affected
in the 2Tg mice, we directly compared responses in The 3Tg-AD mice that we describe here develop an
age-related and progressive neuropathological pheno-the CA1 hippocampal region to those obtained with the
3Tg-AD and PS1-KI mice (Figure 6F). We found that type that includes both plaque and tangle pathology.
Both of these hallmark lesions appear to be mainly re-the LTP response in the 2Tg mice was comparable
to those observed in NonTg mice, particularly in the stricted to the hippocampus, amygdala, and cerebral
cortex—the most pronounced brain structures im-maintenance and late phase of LTP. There was, how-
ever, a decrease in short-term potentiation as compared pacted by AD pathology. In addition, the neuropathology
initiates with a regional pattern closely mimicking thatto PS1-KI mice, suggesting that overexpression of mu-
tant tau may exert subtle synaptic effects on plasticity. observed in AD. Although there is some heterogeneity
as to where A first accumulates in the human brain,These findings suggest that the pronounced LTP deficits
that are apparent in the 3Tg-AD mice are due to the more often than not, deposition begins in cortical re-
gions and later in the hippocampus. In contrast, tangleintracellular accumulation of A. It is evident from these
results that the various mutant transgenes all affect syn- formation typically initiates in limbic brain structures and
then progresses to cortical regions (Mesulam, 1999).aptic functioning to some degree but that intraneuronal
accumulation of A underlies the marked deficit in LTP This is precisely the pattern of progression that we ob-
served in the 3Tg-AD mice. Moreover, the penetranceand also the negative effect on PPF. Acute application
of extracellular protofibrillar A has also been shown to of the phenotype is 100%, and both male and female
mice seem to be equally affected. This latter aspectmodulate LTP in rat brain slices (Walsh et al., 2002).
To determine if extracellular protofibrillar A species distinguishes the 3Tg-AD mice from other models in
which one gender seems to be preferentially more vul-underlies the synaptic dysfunction in our model, we uti-
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Figure 7. Intraneuronal A Underlies the Synaptic Dysfunction
(A–C) Immunolabeling of hippocampal brain sections with A42-specific antibody in 1- (A) and 6-month- (B) old 3Tg-AD mice and in 6-month-
old 2Tg mice (C).
(D) Immunoblot showing that steady-state levels of human tau are comparable in the 2Tg and 3Tg-AD mice.
(E and F) Despite equivalent expression of human tau protein, the appearance of tau-immunoreactive neurons is delayed in the 2Tg mice
compared to 3Tg-AD mice. Shown here is an 18-month-old 2Tg (E) versus a 12-month-old 3Tg-AD (F) mouse, respectively.
(G–I) Brain sections from 12-month-old G6 3Tg-AD mouse showing A immunostained neurons in the hippocampus (G) and tau-reactive
neurons in the hippocampus (H) and amygdala (I).
(J–L) Protofibrillar A deposits are apparent in older but not younger 3Tg-AD mice. At 6 months of age, no extracellular protofibrillar A is
apparent in the hippocampus, consistent with the synaptic dysfunction being due to intraneuronal A accumulation (J). Low- and high-
magnification views of a 12-month-old 3Tg-AD mouse showing extracellular protofibrillar deposits (K and L).
Original magnifications, 5 (A, G, H, J, and K), 10 (I), 20 (B and M).
nerable (Lewis et al., 2001). The root of this sexual dimor- Mounting evidence points to alterations in synaptic
integrity and plasticity as an early phenotypic manifesta-phism between these models is not clear, although dif-
ferences in the genetic background may be a factor. tion in the pathogenesis of AD and specifically to A as
the underlying factor that induces changes in synaptic
function (see Selkoe [2002] for review). Synapse densitySynaptic Plasticity in Alzheimer’s Disease
One of the main findings of this study is that synaptic is significantly decreased in the AD brain (Terry et al.,
1991). Synapse loss, as reflected by changes in thedysfunction is an early change that precedes the accu-
mulation of the hallmark pathological lesions. Another presynaptic marker synaptophysin, correlates better
with cognitive deficits than either plaques or tanglescritical finding is that the deficits in synaptic plasticity
appear to be triggered by APP overexpression, most (DeKosky and Scheff, 1990; Dickson et al., 1995; Sze et
al., 1997; Terry et al., 1991). The 3Tg-AD mice reportedlikely due to A (see discussion below). Notably, LTP
was not significantly impaired in the 2Tg mice, nor did here and other APP models harboring various missense
mutations exhibit deficits in basal synaptic transmis-tau overexpression mitigate the PS1-mediated effects
on PPF. Nevertheless, it is probable that altered tau sion, with or without LTP deficits (Chapman et al., 1999;
Fitzjohn et al., 2001; Hsia et al., 1999; Moechars et al.,will be found to also affect synaptic plasticity in older
transgenic mice. 1999). Particular forms of A, which may be differentially
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achieved in the various models, may underlie the However, even if some extracellular A is present well
below the limit of detection, it is implausible that suchchanges in synaptic efficacy. LTP was inhibited follow-
ing the intracerebroventricular injection of oligomeric miniscule amounts would exert such profound effects
on synaptic plasticity. Therefore, based on the prepon-A forms into the rat hippocampus (Walsh et al., 2002),
although it is important to consider that the application derance of data, we favor the conclusion that the
intraneuronal accumulation of A (or, alternatively, anof exogenously applied A may produce acute effects
or involve a different mechanism than that achieved via A-containing APP derivative) contributes to the deficits
in synaptic plasticity.its gradual buildup with aging. Finally, a recent report
finds that neuronal activity can also modulate APP pro-
cessing; these authors further propose that APP pro-
Concluding Remarkscessing and neural activity may be linked through a
As is the case in human AD, we find that A depositsnegative feedback loop (Kamenetz et al., 2003). There-
precede tau alterations in the 3Tg-AD mice. Becausefore, there is increasing appreciation from in vitro and
the APP and tau transgenes are expressed to compara-in vivo models for the significant early role that synaptic
ble levels, we believe the sequence of neuropathologicaldysfunction may play in the disease process.
development in the 3Tg-AD mice is consistent with
the amyloid cascade hypothesis. The fact that these
A Pathogenic Role for Intracellular A mice overexpress a mutant tau transgene and not the
in Synaptic Plasticity wild-type isoform may complicate the interpretation;
Intracellular A immunoreactivity is the first clear neuro- however, it is likely that mutant tau will drive the pathol-
pathological manifestation in the brains of these 3Tg- ogy more severely than wild-type tau. Yet, despite this
AD mice. There is evidence that intracellular A deposi- and the equivalent overexpression of the APP and tau
tion may be important in the pathogenesis of AD (Gouras transgenes, A pathology still emerges first, where it
et al., 2000; LaFerla et al., 1997), Down’s syndrome (Gy- may be poised to influence the development of the tau
ure et al., 2001), and in the muscle disorder inclusion neuropathology.
body myositis (Mendell et al., 1991; Sugarman et al., Despite equivalent tau overexpression between the
2002). Intraneuronal A has also been documented in 2Tg and the 3Tg-AD mice, the 2Tg mice do eventu-
the brains of other AD-transgenic mouse models (Chui ally develop tau pathology, although the time frame is
et al., 1999; Kuo et al., 2001; LaFerla et al., 1995; Li et al., significantly delayed with respect to the 3Tg-AD mice.
1999; Wirths et al., 2001). Microinjection of nonfibrillar or Likewise, despite the equivalent overexpression of hu-
fibrillar A42 but not A40 in cultured human primary man tau in both models, LTP is not significantly impaired
neurons leads to their degeneration, although its extra- at the age tested, which is not the case for the 3Tg-
cellular application was without effect (Zhang et al., AD mice. This finding provides strong evidence that
2002). The pathophysiological relevance of intraneuronal intracellular A accumulation underlies the synaptic
A in vivo, however, was not clear. Here, we show for dysfunction that occurs in the 3Tg-AD mice, although
the first time (to our knowledge) that the occurrence subtle synergistic effects with tau cannot be excluded.
of intraneuronal A immunoreactivity in CA1 pyramidal The progressive development of both plaques and
neurons correlates with impairments in synaptic plastic- tangles in an age- and region-dependent manner in the
ity, including deficits in LTP. Immunoelectron micro- 3Tg-AD mice has important clinical implications. Be-
scopic studies show that intraneuronal A42 localizes sides more closely mimicking the neuropathology of
to multivesicular bodies of neurons within presynaptic AD, it should help establish if a therapeutic intervention
and postsynaptic compartments (Takahashi et al., targeted against one of the hallmark lesions is effective
2002), and it would be interesting to determine if the at halting or ameliorating the progression of the other.
same occurs in the 3Tg-AD mice. For example, it will be important to determine if clear-
The finding that synaptic transmission and LTP defi- ance of A deposits affect the subsequent development
cits precede overt plaque and tangle formation in the of tangles, as well as its impact on synaptic plasticity.
3Tg-AD mice implies that synaptic dysfunction is an
early manifestation of AD and that extracellular Adepo-
Experimental Proceduressition is not the causal factor underlying the synaptic
dysfunction. This result agrees with other transgenic Generation of 3Tg-AD Mice
studies showing that synaptic transmission can be im- Human APP (695 isoform) cDNA harboring the Swedish double mu-
tation (KM670/671NL) was subcloned into exon 3 of the Thy1.2pacted independent of plaque formation (Hsia et al.,
expression cassette. Human four-repeat tau without amino terminal1999). That intracellular A plays a pathogenic role in
inserts (4R0N) harboring the P30lL mutation was also subcloned intoAD is intriguing. However, it is likely to remain an unset-
Thy1.2 expression cassette. After restriction digestion to liberate thetled topic because of the inherent difficulty in obtaining
transgene, each fragment was purified by sucrose gradient fraction-
biochemical confirmation that the putative intracellular ation, followed by overnight dialysis in injection buffer (10 mM Tris
species is Aand not another A-containing APP deriva- [pH 7.5], 0.25 mM EDTA). Equal molar amounts of each construct
were comicroinjected into the pronuclei of single-cell embryos har-tive or due to contamination. Although it cannot be ruled
vested from homozygous PS1M146V knockin mice (Guo et al., 1999).out that small amounts of extracellular A underlie the
The PS1 knockin mice were originally generated as a hybrid 129/synaptic deficits in these mice, this appears to be un-
C57BL6 background (Guo et al., 1999). Transgenic mice were identi-likely because no extracellular A was observed in the
fied by Southern blot analysis of tail DNA as described previously
hippocampus at the ages used for the physiology exper- (LaFerla et al., 1995; Sugarman et al., 2002). Founder mice were
iments, despite using a wide battery of A-specific anti- backcrossed to the parental PS1 knockin mice. Both hemizygous
and homozygous 3Tg-AD mice are propagated to study the effectsbodies (including protofibrillar-specific A antibodies).
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ELISAs and Immunoblot
A ELISAs were performed essentially as described previously (Su-
Referenceszuki et al., 1994). For immunoblot, brains from transgenic and control
mice were dounce homogenized in a solution of 2% SDS in H20
Bliss, T.V., and Collingridge, G.L. (1993). A synaptic model of mem-containing 0.7 mg/ml Pepstatin A supplemented with complete Mini
ory: long-term potentiation in the hippocampus. Nature 361, 31–39.protease inhibitor tablet (Roche 1836153). The homogenized mixes
Caroni, P. (1997). Overexpression of growth-associated proteins inwere briefly sonicated to shear the DNA and centrifuged at 4C for
the neurons of adult transgenic mice. J. Neurosci. Methods 71, 3–9.1 hr at 100,000  g. The supernatant was used for immunoblot
analysis. Proteins were resolved by SDS/PAGE (10% Bis-Tris from Chapman, P.F., White, G.L., Jones, M.W., Cooper-Blacketer, D.,
Invitrogen) under reducing conditions and transferred to nitrocellu- Marshall, V.J., Irizarry, M., Younkin, L., Good, M.A., Bliss, T.V., Hy-
lose membrane. The membrane was incubated in a 5% solution of man, B.T., et al. (1999). Impaired synaptic plasticity and learning in
nonfat milk for 1 hr at 20C. After overnight incubation at 4C with aged amyloid precursor protein transgenic mice. Nat. Neurosci. 2,
the primary antibody, the blots were washed in Tween-TBS for 20 271–276.
min and incubated at 20C with the secondary antibody. The blots Chui, D.H., Tanahashi, H., Ozawa, K., Ikeda, S., Checler, F., Ueda, O.,
were washed in T-TBS for 20 min and incubated for 5 min with Suzuki, H., Araki, W., Inoue, H., Shirotani, K., et al. (1999). Transgenic
Super Signal (Pierce). mice with Alzheimer presenilin 1 mutations show accelerated neuro-
degeneration without amyloid plaque formation. Nat. Med. 5,
560–564.Immunohistochemistry
Formalin-fixed, paraffin-embedded brains were sectioned at 5 m, DeKosky, S.T., and Scheff, S.W. (1990). Synapse loss in frontal cor-
tex biopsies in Alzheimer’s disease: correlation with cognitive sever-mounted onto silane-coated slides and processed as described.
The following antibodies were used: anti-A 6E10 and 4G8 (Signet ity. Ann. Neurol. 27, 457–464.
Laboratories, Dedham, MA), anti-A 1560 (Chemicon), A11 (Kayed Dickson, D.W., Crystal, H.A., Bevona, C., Honer, W., Vincent, I., and
et al., 2003), anti-APP 22C11 (Chemicon), anti-Tau HT7, AT8, AT180 Davies, P. (1995). Correlations of synaptic and pathological markers
(Innogenetics), Tau C17 (Santa Cruz), Tau 5 (Calbiochem), anti-GFAP with cognition of the elderly. Neurobiol. Aging 16, 285–304.
(Dako), and anti-actin (Sigma). Primary antibodies were applied at
Fitzjohn, S.M., Morton, R.A., Kuenzi, F., Rosahl, T.W., Shearman,dilutions of 1:3000 for GFAP; 1:1000 for 6E10; 1:500 for 1560, AT8,
M., Lewis, H., Smith, D., Reynolds, D.S., Davies, C.H., Collingridge,AT180, and Tau5; and 1:200 for HT7.
G.L., et al. (2001). Age-related impairment of synaptic transmission
but normal long-term potentiation in transgenic mice that over-
express the human APP695SWE mutant form of amyloid precursorElectrophysiology
protein. J. Neurosci. 21, 4691–4698.Mice were anaesthetized with halothane, decapitated, and the
brains were rapidly removed in ice-cold artificial cerebrospinal fluid Flood, D.G., and Coleman, P.D. (1990). Hippocampal plasticity in
(aCSF; 125 mM NaCl, 2.5 mM KCl, 1.25 mM KH2PO4, 25 mM NaHCO3, normal aging and decreased plasticity in Alzheimer’s disease. Prog.
1.2 mM MgSO4, 2 mM CaCl2, and 10 mM dextrose, bubbled with Brain Res. 83, 435–443.
95% O2, 5% CO2 [pH 7.4]). Transverse hippocampal slices (400 m) Gotz, J., Chen, F., Barmettler, R., and Nitsch, R.M. (2001a). Tau
were prepared in aCSF using a vibroslice and left to equilibrate for filament formation in transgenic mice expressing P301L tau. J. Biol.
at least 1 hr prior to recording in a holding chamber containing aCSF Chem. 276, 529–534.
at room temperature.
Gotz, J., Chen, F., van Dorpe, J., and Nitsch, R.M. (2001b). FormationSlices were placed in an interface chamber, continuously perfused
of neurofibrillary tangles in P301l tau transgenic mice induced bywith aCSF at 34C, and covered with a continuous flow of warmed
Abeta 42 fibrils. Science 293, 1491–1495.humidified gas (95% O2, 5% CO2). Field excitatory postsynaptic
potentials (fEPSPs) were recorded in the stratum radiatum of the Gouras, G.K., Tsai, J., Naslund, J., Vincent, B., Edgar, M., Checler,
F., Greenfield, J.P., Haroutunian, V., Buxbaum, J.D., Xu, H., et al.CA1 using glass microelectrodes (1–5	,  5 m diameter) filled
with aCSF. Synaptic responses were evoked by stimulation of the (2000). Intraneuronal Abeta42 accumulation in human brain. Am. J.
Pathol. 156, 15–20.Schaffer collateral/commissural pathway with a concentric bipolar
stimulating electrode with 0.1 ms pulse width. Input/output curves Grundke-Iqbal, I., Iqbal, K., George, L., Tung, Y.C., Kim, K.S., and
were generated using stimulus intensities from 0 to 300 A in incre- Wisniewski, H.M. (1989). Amyloid protein and neurofibrillary tangles
ments of 20 A. PPF was assessed using an interstimulus interval coexist in the same neuron in Alzheimer disease. Proc. Natl. Acad.
of 50 ms. Baseline fEPSPs were evoked at 30% of the max fEPSP Sci. USA 86, 2853–2857.
for 15 min prior to HFS. LTP was induced at baseline intensity using
Guo, Q., Fu, W., Sopher, B.L., Miller, M.W., Ware, C.B., Martin, G.M.,high-frequency stimulation (HFS) consisting of four trains of 100 Hz
and Mattson, M.P. (1999). Increased vulnerability of hippocampalstimulation at 20 s intervals. Recordings were made every 30 s for
neurons to excitotoxic necrosis in presenilin-1 mutant knock-in60 min after HFS. The maximum fEPSP slopes were measured offline
mice. Nat. Med. 5, 101–106.using Axograph software and were expressed as a percentage of
Gyure, K.A., Durham, R., Stewart, W.F., Smialek, J.E., and Troncoso,the average slope from the 15 min of baseline recordings. In some
J.C. (2001). Intraneuronal abeta-amyloid precedes development ofexperiments, the stimulus intensity was raised so that baseline EPSP
amyloid plaques in Down syndrome. Arch. Pathol. Lab. Med. 125,slopes matched the average baseline EPSP in the NonTg mice (usu-
489–492.ally an EPSP0.7mV in amplitude). Data were expressed as mean
SEM and assessed for significance using the Student’s t test. Hardy, J., and Selkoe, D.J. (2002). The amyloid hypothesis of Alzhei-
mer’s disease: progress and problems on the road to therapeutics.
Science 297, 353–356.
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